2016 American Transplant Congress
Twenty Years of Evolving Trends in Racial Disparities for Adult Kidney Transplant Recipients.
Med Univ of South Carolina, Charleston, SC.
Objective: To determine if baseline risks and post-transplant outcome disparities in African American (AA) kidney transplant recipients have evolved over time.Methods: Analysis of 20-years of…2016 American Transplant Congress
The Impact of Body Mass Index > 35 on Kidney Transplant Outcomes: A Systematic Review.
Organ Transplant, University of Illinois Hospital and Health Sciences System, Chicago, IL.
Background: The increased prevalence of obesity (BMI > 30) among adults in the United States over the last two decades is reflected in the number…2016 American Transplant Congress
The Impact of Ritonavir-Boosted Protease Inhibitors and Non-Depleting Antibody Induction on Outcomes in HIV-Infected Kidney Transplant Recipients.
Mount Sinai Hospital, New York.
Background: One-year rejection rates in HIV-infected kidney transplant recipients range from 15-40%, compared to overall rejection rates of 10% in HIV-negative patients. Protocols for immunosuppression…2016 American Transplant Congress
Induction Therapy with Depleting Antibodies in Low Immunological Risk Renal Transplant Patients Treated with a Steroid Free Regimen – Comparison of Alemtuzumab vs. Antithymocyte Globulin.
Induction therapy with depleting antibodies reduces rejection rate and potentially improves efficacy of steroid free regimens after renal transplantation.This prospective, single-centre, cohort study evaluated cumulative…2016 American Transplant Congress
Associations of Risk Factors and Kidney Retransplant Outcomes Vary Between Three Common Induction Agents: Results from the Analysis of Over Ten-Thousand Cases in Ten Years.
Medicine, University of Florida, Gainesville, FL.
BACKGROUND: There is no published study comparing the significance of risk factors for graft outcomes associated with common induction regimens combined with tacrolimus and mycophenolate…2016 American Transplant Congress
Outcomes of Depleting Antibody Induction in Kidney Transplantation: A Paired Kidney Analysis.
Nephrology and Hypertension, Allegheny General Hospital, Pittsburgh, PA.
Induction therapy can improve graft survival following kidney transplantation. Organ quality, a major determinant of graft outcomes may act as a confounder in comparative studies…2016 American Transplant Congress
Induction Immunosuppression and Post-Transplant Outcomes in Kidney Recipients with Hepatitis C Virus.
Kidney transplantation is a well-established treatment option for ESRD patients with Hepatitis C virus (HCV). However, the optimal induction regimen for this population is uncertain,…2016 American Transplant Congress
Tailored Rabbit Anti-Thymocyte Globulin Induction (rATG) Dosing for Kidney Transplantation.
1MMC, Portland, ME; 2MGMC, Augusta, ME.
Purpose: Although rATG is the most commonly used induction immunotherapy for kidney transplantation (KT), optimal dosing remains unknown. In order to minimize adverse effects and…2016 American Transplant Congress
Antithymocyte Globulin (ATG) versus Anti-interleukin-2 Receptor (Anti-IL-2R) as Induction Therapy for Kidney Transplantation After a Nonrenal Transplant.
Patients undergoing kidney transplant after a previous nonrenal organ transplant (NRT) present a small but emerging subpopulation of kidney transplant recipients. Little is known about…2016 American Transplant Congress
Initial Experience Treating Hepatitis C Positive Kidney Transplant Recipients with Non-Interferon-Containing Regimens: Successes and Challenges.
Weill Cornell Medical College, New York, NY.
Historically, treatment of hepatitis C virus (HCV) infection with interferon-based regimens after kidney transplantation has been associated with risk of rejection & graft loss. Direct…
American Transplant Congress abstracts